Abstract
Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Current Pharmaceutical Design
Title: Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder
Volume: 18 Issue: 4
Author(s): A. Bechdolf, A. Ratheesh, S. J. Wood, T. Tecic, P. Conus, B. Nelson, S. M. Cotton, A. M. Chanen, G. P. Amminger, S. Ruhrmann, F. Schultze-Lutter, J. Klosterkotter, P. Fusar Poli, A. R. Yung, M. Berk and P. D. McGorry
Affiliation:
Keywords: Bipolar disorder, at-risk criteria, prodrome, conversion, prediction, mania, depression, neuroprogression, psychosis, hallucinations
Abstract: Bipolar affective disorder (BD) is a severe, recurrent and disabling disorder with devastating consequences for individuals, families and society. Although these hazards and costs provide a compelling rationale for development of early detection and early intervention strategies in BD, the development of at-risk criteria for first episode mania is still in an early stage of development. In this paper we review the literature with respect to the clinical, neuroantomical and neuropsychological data, which support this goal. We also describe our recently developed bipolar at-risk criteria (BAR). This criteria comprises the peak age range of the first onset of bipolar disorder, genetic risk, presenting with sub-threshold mania, cyclothymic features or depressive symptoms. An initial pilot evaluation of the BAR criteria in 22 subjects indicated conversion rates to proxies of first-episode mania of 23% within 265 days on average, and high specificity and sensitivity of the criteria. If prospective studies confirm the validity of the BAR criteria, then the criteria would have the potential to open up new avenues of research for indicated prevention in BD and might therefore offer opportunities to ameliorate the severity of, or even prevent BD.
Export Options
About this article
Cite this article as:
Bechdolf A., Ratheesh A., J. Wood S., Tecic T., Conus P., Nelson B., M. Cotton S., M. Chanen A., P. Amminger G., Ruhrmann S., Schultze-Lutter F., Klosterkotter J., Fusar Poli P., R. Yung A., Berk M. and D. McGorry P., Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316226
DOI https://dx.doi.org/10.2174/138161212799316226 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists
Current Medicinal Chemistry Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Roles of CLR/RAMP Receptor Signaling in Reproduction and Development
Current Protein & Peptide Science Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity:Role of Sympathetic Nerve Activity and Insulin Resistance
Current Diabetes Reviews Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Evaluation of Salivary Melatonin Levels in HIV-positive Patients: A Historical Cohort Study
Reviews on Recent Clinical Trials Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry DNA Repair in Normal and Cancer Stem Cells, with Special Reference to the Central Nervous System
Current Medicinal Chemistry Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Matrix Metalloproteinase Dependent Cleavage of Cell Adhesion Molecules in the Pathogenesis of CNS Dysfunction with HIV and Methamphetamine
Current HIV Research Molecular Genetics of Left Ventricular Dysfunction
Current Molecular Medicine The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology